Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, transparency must come first. Of its followed by positive developments, kaboom. But you're right, without the filings first, any news about future deals will be seen negatively
I was just about to ask for thoughts about what the Q's might say about all that's transpired. Then I saw that 800K on the ask at .0049
Is this any indication?
Everyone has been waiting for statements but maybe that begs the age old adage, be careful what you wish for.
Sounds like a reasonable conclusion
This puppy has been on the fence a long time. Its gonna go one way or another, either a news release coming soon that sends it north or a filing for bankruptcy.
GLTA
I like this company and love the idea. I think, long term, looking good. Failure to break resistance and with yesterday and today's action so far, maybe the market has decided to back away for a bit? I hope so, good opportunity to load up!
GLTA
I'm not in yet, been keeping an eye out though. I am and have been trading NatGas. Obviously, got whacked recently but oh well. With the draw down and a weakened polar vortex, I think it only takes a mention of a cold snap later this month to send natgas and anything tied to it roaring up.
GLTA
And then that happened.
Don't be fooled though, it may be coming:
https://www.aer.com/science-research/climate-weather/arctic-oscillation
Weak PV means $$$ by seasons end!
Good day all-
I'm new to this one, just picked up some calls because I believe natural gas will begin trending higher. Seems like this winter will bring colder temps than seen in the previous two. Also, the incoming administration has made some promises to the folks in the coal industry that need to be kept. The best way to make coal competitive is find a way to increase the price of natural gas. This is an oversimplification of course, but in general, this seems a logical course in the coming months.
That said, I'm concerned that this fund hasn't followed the price of the underlying commodity as closely as I would expect. Any thoughts as to why?
GLTA
John, thanks for the info! Yes, the going concern stuff sounds like generic language. I do have concerns that the company is having difficulty meeting debt obligations and even paying rent. I'm anxious to hear how your communication with the CEO goes. Thanks again.
GLTA
I let the last Q scare me and stayed away, mostly due to commentary about the numbers indicating it will be difficult to be a going concern. Probably just boiler plate language but it got to me. For those of you who hung on or bought the dip, congratulations and Merry Christmas! I'm jumping in next week on any dip, long term play, plenty of room to run in 17 if they can get financing/partnerships.
GLTA
Finally read the December Q. Yikes! Writing is on the wall, too bad, neat idea.
Preparing to launch Phase I/II this quarter. It will interesting to see how long it takes for others to catch on.
BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
9:33 am ET April 5, 2016 (Market Wire) Print
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and effort in preparing for the anticipated Phase I/II clinical trial.
Based upon the Company's current discussions with its partners, BriaCell believes it will be in a position to launch the trial within this current quarter. The Company is working diligently on a number of key initiatives including completion of its vaccine manufacturing, coordinating clinical sites, and finalizing its Contract Research Organization (CRO). The Company hopes to provide further updates on all fronts in the near future.
Dr. Babaei, Chairman of the Board noted, "BriaCell is now in the final stages of preparations for its clinical trial with its lead cancer vaccine, BriaVax(TM). BriaCell is excited about entering the clinic in order to dose patients and hopefully expand upon its Phase I results. Additionally, the trial will serve to advance BriaCell's R&D platform through utilizing future BriaVax(TM) data in complementing its existing gene signature announced last week. We will continue to take steps to work with partners and contractors who can meet our demanding standards and timelines."
Manufacturing of the vaccine is nearing completion at the facilities of BriaCell's partner, University of California Davis. As prior noted, UC Davis is manufacturing compliant cGMP-grade BriaVax(TM) which will be used in dosing patients during the upcoming trial. The Company has already been notified that several BriaVax batches have been completed, and hopes to report further on this matter in the coming weeks.
Upon receiving FDA authorization 5 months ago, BriaCell embarked on identifying a suitable CRO partner in order to facilitate the trial. The Company is at the final stages of negotiations and hopes to report further on this within the coming weeks.
BriaCell has been in discussions with potential sites at which it would recruit and dose patients during its Phase I/II. These sites are primarily university-hospitals with large patient populations who might be matches for BriaCell's trial. BriaCell hopes to update further on this matter in the near future.
About BriaCell
BriaCell is an immuno-oncology biotechnology company which recently received FDA authorization to advance into a Phase I/II clinical trial for advanced breast cancer and possibly other cancer types.The Company has demonstrated unique highly promising results, wherein certain patients saw 3-5x survival vs. typical life expectancy for Stage-IV breast cancer patients. BriaCell is intent on building upon these results to further advance BriaVax(TM) through FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase-I clinical trials, one conducted using BriaVax(TM), the other using a related vaccine, have been encouraging in terms of both safety and efficacy in patients with advanced breast cancer. Most uniquely, BriaCell has achieved these results in patients who had prior failed the available therapies including various kinds of chemotherapy. In some cases, the survival was three to five times longer than expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.
In one patient, cancer regressed at all sites, including lesions in the breast, lung, and even brain. Again, results were seen rapidly and with little to no adverse side effects.
Reader Advisory
Statements in this press release may contain forward-looking information. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expects" and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law. NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
Contact BriaCell
www.BriaCell.com
820 Heinz Avenue
Berkeley, CA, 94710
Farrah Dean
1-888-485-6340
farrah@BriaCell.com
SOURCE: BriaCell Therapeutics Corp.
And the buyback will not be taking place in the very near future.
Everyone's waiting for the 10K...
and we get another company update talking about all the promising future prospects. Translation: no 10K this week and here comes the E. I may buy some in the trips.
Good luck ladies and gentlemen.
Yep... I'm back. Had my sell in at .006 and would have been ok to be out at that. This one's been rode hard and put away wet.
This is a big problem
You put out a PR touting the 7th as the global release of your android app and then nothing? I smell a scam here and will be exiting tomorrow. GLTA
Good for you! I was on the bid for 230,000 at .0038, got partially filled and said "!@#$" that, finished my order at .004
I was wondering who the lucky SOB that bought at .0037 right after me was. Good luck to all... I think next week will be interesting!!!!!
How do you like it?
Free!!! Free version of the app coming out. Smart. If they truly want to be picked up by one of the bigs, this is the way to get their attention. Up.
I love this company! Tried posting over on YMB but no one there. The low price is perfect and thank God for no promotion and hype, just great science. I'm hoping to accumulate a ton.
GLTA!
Got it. Agreed, though the way it's beginning to trade seems like perhaps something's cookin. Standing by to stand by...
Where are you getting that?
I had to bug out on this one, luckily with a minimal loss. I find it impossible that anyone could spend more than a fleeting moment with this company and not discover this is a total sham.
GLTA anyways.
My biggest concern is the reaction of the Chinese investment firm. Perhaps they already knew this, as one would think a thorough audit would be par for the course prior to such a joint venture. Maybe that's how this came up. If not, then the pps is about to do it's best imitation of the titanic. If I'm about to write my new partner a $3.7 check and they tell me they made a $2.3 screw-up, Houston, we have a major freakin problem!
Management is continuing to assess the Company’s internal control over financial reporting and its disclosure controls and procedures, and expects to report material weakness in its internal control over financial reporting through the present time, due to its failure to properly account for the debt and equity transactions. Management will fully report its conclusion on internal control over financial reporting and disclosure controls and procedures upon completion of the restatement process. We have retained an outside accounting firm to assist in our financial statements and to improve our controls.
NOT GOOD!
Spot on!! Nice DD. We're going up
Check this out:
http://www.smallcapnetwork.com/Cardinal-Resources-Offers-a-Real-and-Real-Quick-Solution-to-the-Clean-Water-Shortage-in-China/s/via/1789/article/view/p/mid/1/id/630/
You'll have to copy and paste into your browser, sorry.
Key point:
Earlier this week, the HangZhou Sky Valley Water Technology Co. - a China-based consortium formed to market and commercialize Cardinal Resources' water treatment technologies in Asia and other international markets - ordered one of these systems, and is planning on buying two more as part of just its initial order.
It was actually a relationship that was quietly forged back on October 13th, when CDNL raised several million dollars worth of funding by selling 51% of itself to this Chinese consortium that didn't just want an investment in a novel idea, but also wanted to build a joint venture that would distribute Red Bird Systems in China. It was the first and last investors heard of it until Monday. Now, that partner/investor has ramped up that relationship by becoming a customer.
NOT JUST AN INVESTOR, A PARTNER AND A CUSTOMER!
Most of my experience is with small cap biotechs and I can tell you from experience, a reverse split almost always drops the price on those guys as it signals weak cash position with continuing expenses. That said, I believe a reverse split, well-timed, with CDNL will ultimately cause the pps to rise so long as the business is growing. An uplisting for this company could be very good if it occurs the way the 8-k indicates it likely will, after the conditions of the second tranche are met. GLTAL!!!!